Why do men's wellness clinics prescribe Arimidex (anastrozole) to male patients?

Why Men's Wellness Clinics Prescribe Arimidex (Anastrozole)

Men's wellness clinics prescribe Arimidex off-label to manage elevated estradiol levels and optimize testosterone-to-estradiol ratios in men with hypogonadism or infertility, despite this being an unapproved use with limited high-quality evidence for efficacy and safety in males.

The Mechanism and Rationale

Anastrozole is an aromatase inhibitor that blocks the conversion of testosterone to estradiol. In men, this mechanism theoretically:

• Reduces estradiol levels
• Increases endogenous testosterone production through reduced negative feedback on the hypothalamic-pituitary-gonadal axis
• Elevates LH and FSH levels
• Improves the testosterone-to-estradiol ratio

The FDA-approved indications for Arimidex are exclusively for postmenopausal women with breast cancer 1. The drug label explicitly states that "the effect of ARIMIDEX in premenopausal women with early or advanced breast cancer has not been studied" and notes that "aromatization of adrenal androgens is not a significant source of estradiol in premenopausal women" 1. There is no FDA approval for use in men.

Clinical Applications in Men's Health

Testosterone Optimization on Testosterone Therapy

When men receive exogenous testosterone replacement, some experience elevated estradiol through aromatization. One practice pattern involves starting anastrozole 0.5 mg three times weekly in men with estradiol >60 pg/mL (regardless of symptoms) or 40-60 pg/mL with symptoms 2. This approach reduced median estradiol from 65 pg/mL to 22 pg/mL while maintaining testosterone levels (616 ng/dL pre-treatment vs 596 ng/dL post-treatment) 2.

Critical caveat: Only 3% of men on testosterone therapy required anastrozole for elevated estradiol in one large practice review 2, suggesting this is not a routine need for most patients.

Male Infertility Treatment

Anastrozole has been used to improve semen parameters in subfertile men. The most predictive factors for response are 3:

• Testosterone-to-LH ratio ≥100 (98% sensitive, 33% specific for improvement)
• Non-azoospermic baseline (men with azoospermia rarely respond)

In responders, anastrozole converted 29% to normozoospermia and enabled 31% of previously ineligible patients to access intrauterine insemination 3. However, men with azoospermia should be counseled on alternative treatments as they rarely benefit 3.

Hypogonadism in Aging/Obese Men

In elderly men (ages 62-74) with mild hypogonadism (testosterone <350 ng/dL), anastrozole 1 mg daily increased:

• Bioavailable testosterone from 99 ng/dL to 207 ng/dL
• Total testosterone from 343 ng/dL to 572 ng/dL
• LH from 5.1 to 7.9 U/L
• While decreasing estradiol from 26 pg/mL to 17 pg/mL 4

Important limitation: These studies showed hormonal changes but no improvements in quality of life, sexual function, or symptom scores over 12 weeks 4.

Safety Concerns Specific to Men

Bone Health

The most concerning finding is decreased bone mineral density at the lumbar spine after 6 months of treatment (mean difference -0.04 gm/cm²) 5. This is particularly problematic given that:

• The FDA label warns extensively about bone loss in women 6
• Aging and obese men may already have compromised bone health
• The European Association of Urology guidelines list aromatase inhibitors as drug-induced causes of hypogonadism 7

Other Adverse Effects

Common side effects in men include 3, 8:

• Anxiety/irritability (reported in multiple studies)
• Decreased libido (paradoxically, despite higher testosterone)
• Elevated hematocrit >54% (requiring monitoring)
• Joint stiffness and arthralgias

Lack of Long-Term Safety Data

The FDA label notes that anastrozole has been tested up to 60 mg in single doses in healthy males and 10 mg daily in women, but there are no long-term safety studies in men 1.

The Evidence Quality Problem

All evidence for anastrozole use in men comes from small, uncontrolled studies or short-term trials. A 2022 meta-analysis included only 3 RCTs (118 patients) and 3 uncontrolled studies (52 patients) 5. The 2021 systematic review on male infertility concluded that use has been "off-label and empirical for decades" 9.

Clinical Decision Algorithm

If considering anastrozole in men:

1. Verify the indication is appropriate:

   • Elevated estradiol on testosterone therapy (>60 pg/mL or >40 pg/mL with symptoms)
   • Male infertility with T:LH ratio ≥100 and non-azoospermia
   • NOT for routine testosterone optimization without elevated estradiol

2. Baseline assessment:

   • Bone mineral density (DEXA scan)
   • Complete hormone panel (total T, bioavailable T, estradiol, LH, FSH)
   • Hematocrit
   • Prostate-specific antigen

3. Dosing:

   • 0.5 mg three times weekly OR 1 mg daily (lower doses may be equally effective) 2, 4

4. Monitoring:

   • Hormone levels at 6-12 weeks
   • Bone density at 6-12 months
   • Hematocrit every 3-6 months
   • Symptom assessment (watch for mood changes, decreased libido)

5. Discontinue if:

   • No hormonal or clinical improvement after 3 months
   • Development of concerning side effects
   • Bone density decline

The Bottom Line

Men's wellness clinics use anastrozole because it effectively manipulates hormone levels, but this practice lacks robust evidence for clinical benefit and carries real risks, particularly to bone health. The drug is being used off-label based on theoretical mechanisms rather than proven improvements in morbidity, mortality, or quality of life. Most men on testosterone therapy do not require estradiol management, and those who do should be carefully selected and monitored 2, 5, 9.